vs
Side-by-side financial comparison of Dayforce (DAY) and EXELIXIS, INC. (EXEL). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $481.6M, roughly 1.2× Dayforce). EXELIXIS, INC. runs the higher net margin — 40.8% vs -40.9%, a 81.7% gap on every dollar of revenue. On growth, Dayforce posted the faster year-over-year revenue change (9.5% vs 5.6%). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 9.8%).
Dayforce, Inc., formerly Ceridian, is an American human resources software and services company.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
DAY vs EXEL — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $481.6M | $598.7M |
| Net Profit | $-196.8M | $244.5M |
| Gross Margin | — | 95.6% |
| Operating Margin | 6.3% | 39.3% |
| Net Margin | -40.9% | 40.8% |
| Revenue YoY | 9.5% | 5.6% |
| Net Profit YoY | -9940.0% | 74.8% |
| EPS (diluted) | $-1.23 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $598.7M | ||
| Q4 25 | — | $597.8M | ||
| Q3 25 | $481.6M | $568.3M | ||
| Q2 25 | $464.7M | $555.4M | ||
| Q1 25 | $481.8M | $566.8M | ||
| Q4 24 | $465.2M | — | ||
| Q3 24 | $440.0M | $539.5M | ||
| Q2 24 | $423.3M | $637.2M |
| Q1 26 | — | $244.5M | ||
| Q4 25 | — | $193.6M | ||
| Q3 25 | $-196.8M | $184.8M | ||
| Q2 25 | $21.3M | $159.6M | ||
| Q1 25 | $14.9M | $139.9M | ||
| Q4 24 | $10.8M | — | ||
| Q3 24 | $2.0M | $118.0M | ||
| Q2 24 | $-1.8M | $226.1M |
| Q1 26 | — | 95.6% | ||
| Q4 25 | — | 96.9% | ||
| Q3 25 | — | 96.6% | ||
| Q2 25 | — | 96.5% | ||
| Q1 25 | — | 96.5% | ||
| Q4 24 | 47.0% | — | ||
| Q3 24 | 45.8% | 96.8% | ||
| Q2 24 | 44.1% | 97.2% |
| Q1 26 | — | 39.3% | ||
| Q4 25 | — | 39.6% | ||
| Q3 25 | 6.3% | 37.6% | ||
| Q2 25 | 9.1% | 33.6% | ||
| Q1 25 | 6.4% | 28.8% | ||
| Q4 24 | 6.1% | — | ||
| Q3 24 | 4.7% | 25.2% | ||
| Q2 24 | 3.3% | 43.3% |
| Q1 26 | — | 40.8% | ||
| Q4 25 | — | 32.4% | ||
| Q3 25 | -40.9% | 32.5% | ||
| Q2 25 | 4.6% | 28.7% | ||
| Q1 25 | 3.1% | 24.7% | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.5% | 21.9% | ||
| Q2 24 | -0.4% | 35.5% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | — | $0.69 | ||
| Q3 25 | $-1.23 | $0.65 | ||
| Q2 25 | $0.13 | $0.55 | ||
| Q1 25 | $0.09 | $0.47 | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $0.01 | $0.40 | ||
| Q2 24 | $-0.01 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $627.6M | $1.1B |
| Total DebtLower is stronger | $631.1M | — |
| Stockholders' EquityBook value | $2.7B | $2.2B |
| Total Assets | $8.7B | $2.8B |
| Debt / EquityLower = less leverage | 0.23× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.1B | ||
| Q4 25 | — | $988.5M | ||
| Q3 25 | $627.6M | $791.1M | ||
| Q2 25 | $625.2M | $1.0B | ||
| Q1 25 | $557.3M | $1.1B | ||
| Q4 24 | $579.7M | — | ||
| Q3 24 | $494.1M | $1.2B | ||
| Q2 24 | $465.4M | $1.0B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $631.1M | — | ||
| Q2 25 | $631.8M | — | ||
| Q1 25 | $632.4M | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — |
| Q1 26 | — | $2.2B | ||
| Q4 25 | — | $2.2B | ||
| Q3 25 | $2.7B | $2.0B | ||
| Q2 25 | $2.7B | $2.1B | ||
| Q1 25 | $2.6B | $2.2B | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.6B | $2.3B | ||
| Q2 24 | $2.5B | $2.1B |
| Q1 26 | — | $2.8B | ||
| Q4 25 | — | $2.8B | ||
| Q3 25 | $8.7B | $2.7B | ||
| Q2 25 | $8.5B | $2.8B | ||
| Q1 25 | $9.5B | $2.9B | ||
| Q4 24 | $9.1B | — | ||
| Q3 24 | $8.1B | $3.0B | ||
| Q2 24 | $9.0B | $2.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.23× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.49× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.2M | $333.5M |
| Free Cash FlowOCF − Capex | — | $332.4M |
| FCF MarginFCF / Revenue | — | 55.5% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | 1.36× |
| TTM Free Cash FlowTrailing 4 quarters | — | $875.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $333.5M | ||
| Q4 25 | — | $290.3M | ||
| Q3 25 | $31.2M | $49.0M | ||
| Q2 25 | $112.7M | $211.4M | ||
| Q1 25 | $49.6M | $240.3M | ||
| Q4 24 | $81.0M | — | ||
| Q3 24 | $91.8M | $271.3M | ||
| Q2 24 | $99.2M | $119.5M |
| Q1 26 | — | $332.4M | ||
| Q4 25 | — | $288.8M | ||
| Q3 25 | — | $46.2M | ||
| Q2 25 | — | $208.5M | ||
| Q1 25 | — | $236.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $263.1M | ||
| Q2 24 | — | $113.0M |
| Q1 26 | — | 55.5% | ||
| Q4 25 | — | 48.3% | ||
| Q3 25 | — | 8.1% | ||
| Q2 25 | — | 37.5% | ||
| Q1 25 | — | 41.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 17.7% |
| Q1 26 | — | 0.2% | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 1.0% |
| Q1 26 | — | 1.36× | ||
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | 5.29× | 1.32× | ||
| Q1 25 | 3.33× | 1.72× | ||
| Q4 24 | 7.50× | — | ||
| Q3 24 | 45.90× | 2.30× | ||
| Q2 24 | — | 0.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DAY
| Dayforce Recurring | $333.0M | 69% |
| Cloud And Bureau Professional Services And Other | $78.5M | 16% |
| Float | $42.2M | 9% |
| Powerpay Recurring | $19.7M | 4% |
| Other Recurring | $8.2M | 2% |
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
